Celltrion to supply Remsima SC, Yuflyma to Norway

The company won the Norwegian government's tender for autoimmune disease treatments and will supply until 2026

Celltrion to supply Remsima SC, Yuflyma to Norway
Dae-Kyu Ahn 1
2024-02-07 15:43:35 powerzanic@hankyung.com
Bio & Pharma

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the biosimilar of Humira to Norway.

The company has won the Norwegian government's tender for autoimmune disease treatment. It will provide Remsima SC and Yuflyma from this month until 2026.

According to the company, the Norwegian government has created a foundation for expanding product prescriptions, thanks to policies encouraging biosimilar and regulations on drug prices to enhance medical accessibility and ease financial burdens.

The two products will be sold directly by the local subsidiary.

Celltrion plans to pursue an evidence-based marketing strategy by securing prescription data through consultation with the Norwegian government and healthcare institutions. 

It aims to expand prescriptions across the entire Nordic region through a data-driven marketing strategy.

Write to Dae-Kyu Ahn at powerzanic@hankyung.com
#Celltrion #Remsima SC #Yuflyma #Humira #infliximab #adalimumab #biosimilar #Nordic

Celltrion, WuXi XDC to develop new antibody-drug conjugates

Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC). In December last year, Celltrion inked the contract development and manufacturing services (CDMO) with WuXi XDC to work on the linker and paylo

Celltrion to export three anticancer drugs to Europe

Celltrion to export three anticancer drugs to Europe

South Korea’s Celltrion Inc. announced on Thursday that it has secured supply contracts for three anticancer biosimilars in European countries including France, Italy, Belgium, and the Netherlands.The company reported successful contracts for the anticancer biosimilars Herzuma (trastuzum

Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman

Celltrion Holdings eyes Nasdaq IPO by early 2025: chairman

Celltrion Group founder and Chairman Seo Jung-jin (left) speaks at J.P. Morgan Healthcare Conference (Courtesy of Celltrion) South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the J.P. Morgan Healthcar

Celltrion to expand Yuflyma supply network in Europe

Celltrion to expand Yuflyma supply network in Europe

South Korea’s Celltrion Inc. announced on Friday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatment of autoimmune diseases to two regions of Italy and a pharmaceutical purchasing organization in the Netherlands. Celltrion secured bids for the Yuf

Celltrion revises up earnings goals to overtake Amgen

Celltrion revises up earnings goals to overtake Amgen

Seo Jung-jin (second from right), founder and chairman of Celltrion, speaks at the J.P.Morgan Health Care Conference on Jan. 10 (Courtesy of Celltrion) Celltrion Inc., South Korea's leading biosimilar maker, on Wednesday expressed its ambition to join the global top 10 biotech and pharmaceutica
(* comment hide *}